- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.05. | Pharmather Holdings Ltd: Pharmather to focus on Medbotx platform | 1 | Stockwatch | ||
| 27.05. | PharmaTher Holdings Ltd.: PharmaTher Evolves Platform Strategy with MEDBOTX Robotic 3D Printing for Personalized Medicines | 232 | Newsfile | MEDBOTX represents the evolution into a broader point-of-care manufacturing platform designed for personalized medicines, peptides and advanced dose formatsPotential U.S. peptide reclassification... ► Artikel lesen | |
| 13.05. | Pharmadrug Inc (2): Pharmadrug, Pharmather to explore PD-001 for hantavirus | 3 | Stockwatch | ||
| 13.05. | Pharmather Holdings Ltd: Pharmadrug, Pharmather to explore PD-001 for hantavirus | 3 | Stockwatch | ||
| PHARMATHER Aktie jetzt für 0€ handeln | |||||
| 13.05. | PharmaTher Holdings Ltd.: PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus | 408 | Newsfile | Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, today announced that... ► Artikel lesen | |
| 22.04. | Pharmather Holdings Ltd: Pharmather hopes programs benefit from executive order | 3 | Stockwatch | ||
| 21.04. | PharmaTher Holdings Ltd.: PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness | 258 | Newsfile | Company believes supportive U.S. policy momentum may strengthen the strategic value of its ketamine patch, KetaVault platform, retained ketamine programs, and prior FDA-approved ketamine ANDA transactionToronto... ► Artikel lesen | |
| 21.04. | Pharmather Holdings Ltd: Pharmather talks up microneedle patch opening in U.S. | 3 | Stockwatch | ||
| 20.04. | PharmaTher Holdings Ltd.: PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides | 475 | Newsfile | U.S. regulatory momentum in psychedelics and peptides could open new commercial opportunities for PharmaTher's PatchPrint automated manufacturing platform and PharmaPatch product platform as an... ► Artikel lesen | |
| 16.04. | PharmaTher Holdings Ltd.: PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery | 511 | Newsfile | Anticipated peptide reclassification could expand the addressable market for PharmaTher's PharmaPatch product strategy and PatchPrint manufacturing platform, strengthening its position in next-generation... ► Artikel lesen | |
| 14.04. | Pharmather Holdings Ltd: Pharmather files U.S. patent for peptide patch tech | 1 | Stockwatch | ||
| 13.04. | PharmaTher Holdings Ltd.: PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology | 392 | Newsfile | Patent filing intended to strengthen PharmaTher's peptide formulation capabilities for PharmaPatch while complementing PatchPrint as part of the Company's broader microneedle patch development and... ► Artikel lesen | |
| 26.03. | Pharmather Holdings Ltd: Pharmather applies for provisional PatchPrint patent | 1 | Stockwatch | ||
| 26.03. | PharmaTher Holdings Ltd.: PharmaTher Introduces PatchPrint With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches | 418 | Newsfile | Leveraging its PharmaPatch experience, the Company is introducing PatchPrint to support existing microneedle patch programs and expand into on-demand personalized patch solutions, including peptide... ► Artikel lesen | |
| 03.03. | Pharmather Holdings Ltd: Pharmather to expand PharmaPatch platform | 2 | Stockwatch | ||
| 03.03. | PharmaTher Holdings Ltd.: PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market | 537 | Newsfile | Toronto, Ontario--(Newsfile Corp. - March 3, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking... ► Artikel lesen | |
| 03.02. | Pharmather Holdings Ltd: Pharmather seeks to commercialize generic semaglutide | 1 | Stockwatch | ||
| 02.02. | PharmaTher Holdings Ltd.: PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success | 982 | Newsfile | Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a specialty pharmaceutical company, today announced a... ► Artikel lesen | |
| 15.01. | Pharmather Holdings Ltd: Pharmather enters obesity market with PharmaPatch | 10 | Stockwatch | ||
| 14.01. | PharmaTher Holdings Ltd.: PharmaTher Expands PharmaPatch Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs | 285 | Newsfile | Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QUANTUM BIOPHARMA | 3,198 | -1,90 % | Quantum BioPharma Provides Corporate Update | THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, June 01, 2026... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 56,38 | +2,92 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| OPUS GENETICS | 3,480 | -1,69 % | Opus Genetics, Inc.: Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases | Rapidly Advancing Five IRD Programs? with Four Clinical Data Readouts Expected in 2027 RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing over the Next 12 to 18 Months Cash Runway into... ► Artikel lesen | |
| PROTHENA | 7,850 | +1,08 % | Prothena Corporation plc: Prothena Reports First Quarter 2026 Financial Results and Business Highlights | Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million
Prothena updates... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 3,460 | -0,57 % | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression | D-Cycloserine (DCS) has been reported to augment the effect of Transcranial Magnetic Stimulation (TMS) in remission from depression and suicidality in several published clinical studies.NRx Pharmaceuticals... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 0,351 | -0,20 % | Reviva Pharmaceuticals: Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights | - Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new form... ► Artikel lesen | |
| ORIC PHARMACEUTICALS | 7,680 | +4,01 % | ORIC Pharmaceuticals: ORIC Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates | Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026 Reported rinzimetostat... ► Artikel lesen | |
| OMNIAB | 2,345 | +0,21 % | OmniAb, Inc. - 8-K, Current Report | ||
| PROCESSA PHARMACEUTICALS | 2,310 | +8,96 % | RedChip Companies, Inc.: Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | ORLANDO, FLORIDA / ACCESS Newswire / January 9, 2026 / RedChip Companies will air interviews with Alliance Entertainment Holding Corp. (Nasdaq:AENT) and Processa Pharmaceuticals, Inc. (Nasdaq:PCSA)... ► Artikel lesen | |
| ONKURE THERAPEUTICS | 4,310 | -3,79 % | OnKure Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| PRF TECHNOLOGIES | 1,610 | -2,42 % | PRF Technologies Ltd. - 6-K, Report of foreign issuer | ||
| PMGC | 1,385 | -0,36 % | Trotz massiver Kursverluste: PMGC-Tochter meldet Patente für Wirkstoffe zum Muskelerhalt an | ||
| NASUS PHARMA | 3,095 | +0,16 % | Nasus Pharma, Ltd.: Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update | Recent Phase 2 topline results demonstrate NS002's potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen®; pivotal study... ► Artikel lesen | |
| BAYER | 38,010 | +2,31 % | EQS-PVR: Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Bayer Aktiengesellschaft
Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
15.06.2026... ► Artikel lesen | |
| MERCK KGAA | 133,30 | +0,19 % | JEFFERIES stuft MERCK KGAA auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Merck KGaA auf "Hold" mit einem Kursziel von 129 Euro belassen. Das Segment Life Science sei ein wesentlicher, mit geringeren... ► Artikel lesen |
Das Unternehmen PHARMATHER HOLDINGS LTD kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +25,00 % bei einem Aktienkurs von 0,030 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMATHER HOLDINGS LTD finden Sie auf Wallstreet Online.